Healthcare and Life Science
New Year, new you, new offer from The Jockey Club
For every NEW conference booked and confirmed to take place from 5th January to 31st March 2023, you can take your pick from a variety of options to add to your Day Delegate package from Danish pastries to fresh fruit platters and add them to your event, completely free of charge! We c...
Cresset January 2023 Newsletter
After a busy start to 2023, our January monthly update newsletter includes features around Flare Visualizer, Virtual Screening, Molecular Dynamics, and more! ...
Recruiting Social Care workers from overseas - Employer's Guide
As part of new temporary measures to address the workforce challenges faced by the health and social care sector in the UK, a number of care sector roles have been added to the UK Shortage Occupation List (SOL) from 16 February 2022, and for 12 months will be eligible for Health and Car...
University of Exeter enters virtual screening collaboration with Cresset Discovery to accelerate discovery of novel antimicrobial drugs
Cresset Discovery, provider of molecular modeling expertise for drug discovery, is collaborating with the University of Exeter to find new antimicrobial drugs. Cresset Discovery will deploy its expertise in virtual screening to identify promising new candidates, building on research led...
Pheno Therapeutics announces worldwide license from UCB to a novel program for neurodegenerative disease
Preclinical program with potential for disease modifying therapeutic
The year in review: Updates and trends
In 2022, everyone witnessed intense activity in matters related to supply chain issues, the energy transition, oil & gas, post-M&A disputes, licensing issues, breaches of distribution contracts and increasingly arbitrations deriving from geopolitical issues in Europe and Asia an...
The FDA further expands collaboration with CN Bio to evaluate the PhysioMimix Multi-organ microphysiological system
CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single-and multi-organ microphysiological systems (MPS), today announced that the U.S. Food and Drug Administration (FDA) and CN Bio have expanded their collaboration for the second time, with new research aim...
Assessing the impact of rarity on French HTA and pricing decisions
With changes to the pricing and access processes such as the new Accord Cadre and the soon-to-be implemented ATU reform likely to impact pricing and access of orphan products in France, Cécile Matthews, Bhavesh Patel, and Owen Male look at how French payers have valu...
How eligible patient numbers affect price of rare disease drugs in France
Having recently assessed the relationship between drug price and prevalence of non-oncology rare diseases, CRA’s Cécile Matthews, Bhavesh Patel, and Owen Male explore in greater depth the situation for these orphan drugs in France in this final article of a three-part series publis...
France’s ATU reform: Early access remains possible, but not all diseases are equal
When France’s ATU reform was implemented, some viewed it as restrictive. In this article published in European Pharmaceutical Review (EPR), Cécile Matthews and Charlotte Capdevila explore the reform’s impact on early access to oncology drugs and products for rare diseases. ...